Effectiveness of sotalol treatment in symptomatic Brugada syndrome

Kathryn A. Glatter; Qing Wang; Mark Keating; Shenghan Chen; Nipavan Chiamvimonvat; Melvin M. Scheinman

doi:10.1016/j.amjcard.2004.02.023

Effectiveness of sotalol treatment in symptomatic Brugada syndrome

Kathryn A. Glatter, Qing Wang, Mark Keating, Shenghan Chen, Nipavan Chiamvimonvat, Melvin M. Scheinman

Cardiovascular Medicine

Research output: Contribution to journal › Article

16 Scopus citations

Abstract

We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.

Original language	English (US)
Pages (from-to)	1320-1322
Number of pages	3
Journal	American Journal of Cardiology
Volume	93
Issue number	10
DOIs	https://doi.org/10.1016/j.amjcard.2004.02.023
State	Published - May 15 2004

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2004.02.023

Fingerprint Dive into the research topics of 'Effectiveness of sotalol treatment in symptomatic Brugada syndrome'. Together they form a unique fingerprint.

Cite this

Glatter, K. A., Wang, Q., Keating, M., Chen, S., Chiamvimonvat, N., & Scheinman, M. M. (2004). Effectiveness of sotalol treatment in symptomatic Brugada syndrome. American Journal of Cardiology, 93(10), 1320-1322. https://doi.org/10.1016/j.amjcard.2004.02.023

@article{ec2770add87a42a2a10939348315681c,

title = "Effectiveness of sotalol treatment in symptomatic Brugada syndrome",

abstract = "We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.",

author = "Glatter, {Kathryn A.} and Qing Wang and Mark Keating and Shenghan Chen and Nipavan Chiamvimonvat and Scheinman, {Melvin M.}",

year = "2004",

month = may,

day = "15",

doi = "10.1016/j.amjcard.2004.02.023",

language = "English (US)",

volume = "93",

pages = "1320--1322",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Effectiveness of sotalol treatment in symptomatic Brugada syndrome

AU - Glatter, Kathryn A.

AU - Wang, Qing

AU - Keating, Mark

AU - Chen, Shenghan

AU - Chiamvimonvat, Nipavan

AU - Scheinman, Melvin M.

PY - 2004/5/15

Y1 - 2004/5/15

N2 - We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.

AB - We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.

UR - http://www.scopus.com/inward/record.url?scp=2342458202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342458202&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.02.023

DO - 10.1016/j.amjcard.2004.02.023

M3 - Article

C2 - 15135718

AN - SCOPUS:2342458202

VL - 93

SP - 1320

EP - 1322

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -